LiqTech International Inc (NYSEMKT:LIQT) is higher Thursday after it returned to profit in Q3 for the first time since Q1 2012. Its earnings topped analysts' expectations; revenue fell short. Shares are up 13.49% at $1.43 in mid-morning trading, moving in a 52-week range of $1.02 - $3.19. The company, which provides technologies for gases and liquid purification by manufacturing ceramic silicon carbide filters, posted Q3 net income of $0.35 million or $0.01 per share, compared with the prior-year period's net loss of $904,000, or $0.04 loss per share. Analysts polled by Capital IQ were expecting a loss of $0.01 per share.Revenue was $4.93 million, up 67% from $2.95 million in the same quarter last year. LiqTech International Inc (NYSEMKT:LIQT) attributes the increase in total sales to higher sales of liquid membranes, including Provital filtration systems (up $1.85 million as compared to last year), and higher DPF filter sales (up $133,000). Analysts were looking for revenues of $5.8 million.Click here for a free comprehensive Trend Analysis ReportGalmed Pharmaceuticals Ltd (NASDAQ:GLMD) shares edged higher Thursday, after the clinical-stage biopharmaceutical company confirmed the first administration of its drug candidate aramchol in a Phase IIa clinical trial for the treatment of cholesterol gallstones. The trial is being conducted at the Assuta Medical Center in Tel Aviv, Israel and is a single center, randomized, double blind, placebo controlled study, designed to evaluate the efficacy and safety of a once-daily dose of aramchol.The primary endpoint of the trial is a complete dissolution of newly formed cholesterol gallstones following bariatric surgery, the biopharmaceutical company said. Galmed expects to report top-line results in the first half of 2015. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) shares were up 0.7% in recent early trading Thursday to $6.07, still near the low end of their 52-week range of $5.33 to $18.73.Click here for a free comprehensive Trend Analysis ReportSally Beauty Holdings, Inc. (NYSE:SBH) reported fiscal Q4 earnings and sales that were just below analysts' estimates. The beauty supplies retailer said adjusted earnings in the quarter ended Sept. 30 rose to $0.39 per diluted share from $0.38 a year earlier compared to the $0.40 average estimate from analysts polled by Capital IQ. Same store sales rose 2.6% in the quarter. Reported income fell to $61.75 million or $64.81 million but rose 2.6% on a diluted share basis to $0.39. Total sales rose 4% to $944 million compared to the $945.4 million consensus.For fiscal 2015, Sally Beauty Holdings, Inc. (NYSE:SBH) said same store sales growth is expected to be slightly above 3%. It said consolidated same store sales growth in the fiscal Q1 may fall below the full year estimate as sequential, quarterly improvement is expected throughout the year. Consolidated organic store growth is expected to be in the range of 3% to 4%.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
